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To date themost common sources of tissue for human embryo
stem cell (hESC) derivation have been fresh or frozen
cleavage- or blastocyst-stage embryos that are surplus to in
vitro fertilization (IVF) requirements. Generally these have
retained some degree of cellular viability such that they are
able to develop to the blastocyst stage in culture without
additional intervention, after which cell lines have been
derived by various means (reviewed by Skottman and
Hovatta, 2006). Human ESC derivation has also been
achieved from singly isolated blastomeres from viable early
embryos (Klimanskaya et al., 2006; Chung et al., 2008) and
with reduced efficiency from poor-quality and fragmenting
cleavage- and morula-stage embryos without progression to
the blastocyst stage (Strelchenko et al., 2004; Lerou et al.,
2008; Zhang et al., 2006). While this progress is significant,
the derivation of stem cell lines from embryos that still have
putative developmental potential can still be criticized for
the potential to conflict with donor primary interests to
conceive, especially when patient donors fail to conceive
with embryos that they have not donated. Such conflict is not
entirely addressed by blastomere biopsy, as such an invasion
of embryo integrity cannot be guaranteed to have no effect
on developmental progression. Not reported to date has
been the prospect of using clinically failed eggs whose
developmental potential requires some form of intervention
to be realized (Brison and Lieberman, 2003). Such tissue is
normally discarded, and the application of experimental
interventions to recover its developmental potential for
fertility treatment would be undesirable owing to the
unknown consequences of the intervention. By contrast,
the use of clinically failed eggs to derive embryos for stem
cells would be a justifiable and valuable alternative to their
disposal, which if successful would have the added benefit of
developing methods and technology that ultimately could
also be considered in the treatment of infertility.
In the normal course of IVF, between 1 and 3 of every 10
eggs typically recovered from a treatment cycle are
classified as clinically failed and unsuitable for use in
assisted conception. This includes immature eggs that have
failed to complete meiotic progression to metaphase II and
are unsuitable for intracytoplasmic sperm injection (ICSI),
those that fail to fertilize 20–30 h post in vitro insemination
or ICSI (i.e., as assessed by absence of pronuclei), and those
that fertilize abnormally (i.e., possessing one or more than
two pronuclei). Prior research has demonstrated that the
developmental potential of at least a small proportion of this
tissue (i.e., 5–10%) is recoverable through some form of
experimental intervention. This could include extended
culture under conditions promoting the completion of
maturation, followed by ICSI, or ICSI and parthenogenetic
activation to elicit the cascade of signaling events required
to initiate development (Roberts et al., 2002; Yuzpe et al.,
2000; Morton et al., 1997; Zhang et al., 1999). However, such
procedures are not routinely used clinically out of concern
for the potential to affect adversely the health of resulting
offspring. Another factor is the cost/benefit ratio of applying
these procedures in a busy clinical environment with limited
resources. These concerns do not apply to the recovery of
embryos for nonreproductive purposes such as for the
derivation of stem cells, the normalcy of which can then beassessed in vitro. In this study we report on the feasibility of
deriving a normal euploid and biparental hESC line from a
blastocyst originating from a clinically failed egg, thereby
justifying the utility of this approach.Results
As part of concurrent research to evaluate the efficacy of a
range of intervention strategies to recover the develop-
mental potential of clinically failed eggs we attempted to
derive hESC lines from blastocyst-stage embryos using a
previously proven protocol involving the outgrowth of whole
embryos (without isolation of the inner cell mass) on a
substrate of mitotically inactivated human dermal fibro-
blasts (Fletcher et al., 2006). This technique was applied to a
sample of 8 blastocysts that originated from a total of 579
clinically failed eggs used in a concurrent study. Specifically
blastocysts originated from 2 abnormally fertilized and 6
failed-to-fertilize eggs, the latter following IVF by insemina-
tion (5) and ICSI (1). The abnormally fertilized eggs,
containing three pronuclei (PN), developed to the blastocyst
stage without any intervention. All of the failed-to-fertilize
eggs appeared to be arrested at metaphase II (i.e., exhibited
one polar body and no PN) at the time of assessment. Within
4 h of assessment, approximately 22–24 h after their first
clinical insemination/ICSI, 2 of the failed IVF eggs were
reinseminated by ICSI, with the remainder of the failed IVF
(3) and ICSI (1) being subjected to parthenogenetic activa-
tion. The activation stimulus consisted of a brief (5 min)
treatment with a calcium ionophore followed by short-term
(3 h) culture in the presence of serine protein kinase and
protein synthesis inhibitors. In all cases, activation of failed-
to-fertilize eggs by reinsemination or activation was con-
firmed by visualization of PN at 3 and 6 h postactivation or at
16–20 h post-re-ICSI. Of the 6 that failed to fertilize, 4 (i.e.,
2 reinseminated and 2 activated) formed two PN, with the
remaining activated resulting in one or no PN. All embryos
reached the blastocyst stage at day 5 or 6 after recovery or
intervention, with hESC derivation attempted after assisted
hatching to remove the zona pellucida at 8 days. During the
attempt to derive a cell line, the abnormally fertilized
blastocysts and all but 2 of the failed-to-fertilize blastocysts
(specifically the 2 reinseminated by ICSI) attached to a
substrate of mitotically inactivated human dermal fibro-
blasts (HDF). Most cellular outgrowths failed to continue
growing within a week to a month of attachment. However,
one of these, originating from a failed IVF egg arrested at
metaphase II 20 h postinsemination and forming one large
pronucleus 6 h (but not 3 h) post-parthenogenetic activation,
resulted in a new hESC line. This line is now known as RCM1
(i.e., Roslin Cells Manchester-1; Fig. 1) and has been
deposited in the UK Stem Cell Bank for access by the
research community.
Characterization of RCM1 confirmed that it is a pluripo-
tent hESC line comparable to hESC lines derived from surplus
of infertility treatment embryos. At the time of writing RCM1
had been frozen and thawed and maintained under culture
conditions supporting self-renewal for over 80 passages. This
included on and off of HDF feeders, the latter in HDF
conditioned medium on Matrigel (Becton-Dickinson; Xu et
al., 2001; Fletcher et al., 2006) or purified extracellular
Figure 1 The characterization of RCM1 as a pluripotent hESC line. Undifferentiated colonies of RCM1 on human dermal fibroblast
feeder cells are shown (A) in phase contrast, (B) stained positively for Oct 4 and (C) stained positively for alkaline phosphatase activity.
RCM1 cells in vitro differentiated via embryoid bodies and stained for markers of the three germ layers: (D) muscle-specific actin
(mesoderm), (E) α-fetoprotein (endoderm), and (F) β-tubulin III (ectoderm). A histological assessment was made of teratoma tissue
formed as a result of transplantation of the hESC line, RCM1, into the testis of adult SCID mice. (G) Low-power image showing
heterogeneity of tissue structure in tumor. Identifiable structures include bone (bn), cartilage (ct), connective tissue (cn), and small
cysts (cy); higher power images show (H) neuroectoderm (ne) and neural ganglion (ng) and (I) bone (bn). (J) Cartilage; (K) wall of
primitive intestine, including muscular layer (mu), submucosal tissue (sm), and goblet cells (gc) within epithelium releasing mucus
secretion (mc); (L) primitive kidney consisting of renal corpuscle (rc) and associated tubules (tb). (G–J, L) Weigert's and (K)
hematoxylin and eosin. Scale bars, 100 μm (A–J) and 50 μm (K and L).
190 P.A. De Sousa et al.matrix proteins (laminin, fibronectin, vitronectin, collagen
IV; Ludwig et al., 2006) or in StemPro hESC serum-free
medium on feeders or CELLstart matrix (Invitrogen). Under
all of these conditions supportive of hESC renewal the
standard complement of pluripotency markers was detected
by in situ immunocytochemistry (i.e., alkaline phosphatase,
Oct-4, Nanog) and flow cytometry (i.e., SSEA4, Tra-1-60, Tra-1-81; Fig. 1, Supplementary Fig. 1). To compare RCM1 with
other diploid female hESC lines previously isolated from
supernumerary IVF blastocysts by our group, namely RH1 and
3 (Fletcher et al., 2006), we performed an Affymetrix profile
of gene expression using RNA isolated from cultures of hESCs
maintained under self-renewing conditions. Cluster analysis
of selected markers as reported by the International Stem
191Human embryo stem cells from failed eggsCell Initiative comparison of hESC lines (ISCI, 2007) showed
high overall similarity as expected for cells of the same type.
All three lines generally expressed the anticipated panel of
pluripotency markers, including Oct-4, Nanog, Sox-2,
Dnmt3b, Lin28, CD 9, and others (Fig. 2), while uniformly
exhibiting low levels of other markers (i.e., NR5A2, Noggin,
FoxD3, and FGF5 (not shown)). This analysis also revealed
that RCM1 and RH1, which were isolated under identical
culture conditions/protocols, were more closely matched in
their expression of undifferentiated markers than RH1 and
RH3, which originated from sibling embryos and thus were
genetically related (Fig. 2). RCM1 differed from RH1 and RH3
in expressing significant levels of Xist, suggesting that a
higher proportion of RCM1 cells may have undergone X-
chromosome inactivation.
The pluripotency of RCM1 was assessed in vivo and in
vitro. In the latter case, embryoid body-mediated differ-
entiation yielded cells positive for endodermal (α-fetopro-
tein), mesodermal (muscle-specific actin), and ectodermalFigure 2 Two-way cluster analysis of gene expression for RCM1, R
relative to β-actin (red, high expression with respect to β-actin; blu
were generated for three biological replicates of each of the hESC lin
markers (horizontal axis, gold indicates ES cell markers). Individual
left). RCM1 and RH1 cluster more closely than the genetically relate
culture conditions have a proportionately greater effect on phenoty
similarity, but each displays lower levels of expression of one or two h
lower levels of Kit and FGF4 than either RH1 or RCM1). All three lines e
FGF5 (not shown). RCM1 differs from RH1 and RH3 in expressing
X-chromosome inactivation, whereas RH1 and RH3 have not.(β-tubulin III) lineages, whereas neurosphere-mediated
differentiation yielded neuronal cells positive for tyrosine
hydroxylase (TH), β-tubulin III, nestin, MAP-2, and glial
fibrillary acid protein (GFAP) (Fig. 1; Supplemental Figs. 2
and 3). In vivo RCM1 produced teratomas in SCID mice, which
were restricted to the site of injection (i.e., kidney capsule
or testis). Histological analysis showed that these contained
a broad range of differentiated tissues representative of all
three germ layers (Fig. 1, Supplemental Fig. 3), including
cartilage, bone, muscle, primitive neuroectoderm, neural
ganglia, secretory epithelia, primitive kidney, and connec-
tive tissues. While the cells were still being grown on
feeders, genomic PCR was used on RCM1 hESCs flow sorted
for Tra1-60 and SSEA4 to identify a DNA microsatellite
fingerprint that could distinguish these cells from the feeder
cells themselves (Supplemental Table 1). This revealed that
the line was female (XX) and heterozygous at 11 of 16 loci.
Genomic DNA analysis of tissue type also identified RCM1 as
belonging to blood group A and possessing HLA class I typesH1, and RH3 hESC lines. Data are presented as expression level
e, low expression with respect to β-actin). Hierarchical clusters
es RH1, RH3, and RCM1 (vertical axis) for various lineage-specific
replicates of each cell line cluster together (dendrogram on the
d lines RH1 and RH3, suggesting that exogenous factors such as
pe and gene expression. All three hESC lines show high overall
ESC markers with respect to the other lines (e.g., RH3 expresses
xpressed uniformly very low levels of NR5A2, Noggin, FoxD3, and
significant levels of Xist, suggesting that RCM1 has undergone
192 P.A. De Sousa et al.A⁎-02, A⁎03; B⁎35, B⁎44; Cw⁎04, Cw⁎05; and class II types
DRB1⁎01, DRB1⁎04, DRB4⁎01, and DQB1⁎03, DQB1⁎05. The
RCM1 karyotype was evaluated by G-banding at five
successive passages (p16, 24, 35, 41 and 51), with a minimum
of 20 metaphase spreads assessed at each passage (Supple-
mental Fig. 4). For each assessment, a normal diploid
(2n=46) genotype was observed in the majority of spreads
(i.e., 15–20), with a range of aneuploidies detected singly,
none of which were repeated in other assessments. These
included trisomy 20; losses of chromosomes 1, 4, 8, 9, 12, 24,
17, 20, and 21; and structural anomalies of chromosomes 5,
6, 13, 16, and 20. Of these only the trisomy 20 has been
reported previously (Rosler et al., 2004).
To determine whether RCM1 contained any clinically
known genetic anomalies or mutations we performedFigure 3 Frequency and distribution of RCM1 genetic heterozygos
the RCM1 hESC line reveals a pangenomic heterozygosity consistent
homozygosity observed in parthenogenetic cell lines originating
Heterozygosity was assessed using an Affymetrix 500k combined a
software.comparative genome hybridization using a single-nucleotide
polymorphism (SNP)-based CytoChip array (BlueGnome,
Cambridge, UK) used for clinical diagnostics. This array
screens the genome at a resolution of 565 kb, including
telomeres, and 90 genetic conditions at 100-kb resolution
and revealed no genetic deficiencies (Supplemental Fig. 5).
As it was not clear whether the egg from which RCM1
originated had been penetrated by sperm, or whether sperm
penetration had occurred but there had been a failure to
activate, it was necessary to determine definitively whether
the cell line's genetic origin was exclusively maternal (i.e.,
parthenogenetic) or biparental. To assess this, genomic DNA
from RCM1 was analyzed using a separate SNP array screen,
also providing 500-kb resolution, used by others to discrimi-
nate fertilized from parthenogenetic embryo stem cell linesity. A representative chromosome map of SNP heterozygosity for
with a fertilized embryo genome, distinct from pericentromeric
from activated metaphase II eggs (see Kim et al., 2007a,b).
rray (250K Sty 1 and 250K Nsp1) using Partek Genomics Suite
193Human embryo stem cells from failed eggs(Kim et al., 2007a,b). This revealed a whole-genome pattern
of heterozygosity consistent with cells originating from a
fertilized egg (Fig. 3). These results unambiguously confirm
that RCM1 originated from a biparental embryo whose
developmental initiation was likely rescued by parthenoge-
netic activation.Discussion
Our study provides the first report and characterization of a
normal euploid and biparental pluripotent hESC line origi-
nating from a clinically failed egg whose developmental
potential was rescued by parthenogenetic activation. This
achievement was accomplished without conflicting with
patient donor reproductive interests as the egg would
normally be discarded in the course of clinical treatment.
Uncertainty over the consequences of the intervention would
also normally preclude its application for infertility
treatment.
The parthenogenetic activation treatment used in our
study was based on animal parthenogenesis and cloning
research and comparable to that recently described by
others in the creation of human parthenogenetic embryo
stem cells (De Sousa et al., 2002; Martins da Silva et al.,
2005; Revazova et al., 2007). Our method was designed to
both activate intracellular calcium release and suppress
second polar body emission, the latter of which would be
important to maintain euploidy of an unfertilized egg. In the
event of fertilization, suppression of second polar body
emission would have been anticipated to result in triploidy
(i.e., two replicated but separated maternal genomes and
one unreplicated paternal genome). If this had occurred in
the egg that gave rise to RCM1, then this aneuploidy must
have been corrected in at least a subset of cells that gave rise
to the cell line during subsequent mitotic divisions. Such a
correction has previously been reported in the case of
polyspermic pig eggs inseminated in vitro (Han et al., 1999).
Human parthenogenetic embryos and hESCs have pre-
viously been reported using viable metaphase II-arrested
eggs collected from hormonally stimulated donors using an
activation protocol similar to our own (Lin et al., 2003;
Revazova et al., 2007). In the latter study, activation of 45
eggs resulted in 90 and 50% undergoing cleavage and
blastocyst formation, with a yield of six stem cell lines
(i.e., 13% of eggs or 27% of blastocysts). Although it is
difficult to compare reports, this falls in the upper range of
hESC derivation success from fertilized embryos reported by
others, which can vary from 0 to 37% depending on the
starting material and method used (Zhang et al., 2006;
Fletcher et al., 2006; Ludwig et al. 2006; Klimanskaya et al.,
2006; Lerou et al., 2008; Chung et al., 2008). Relative to
blastocysts, our derivation of one stem cell line from 8
(12.5%) was reasonably successful, suggesting that embryos
reaching this stage were of quality comparable to those
traditionally available. When related to the pool of 579
clinically failed eggs from which the blastocysts originated
our success was less impressive (i.e., 0.2%), although this
calculation is confounded slightly by the fact that the
blastocysts used were provided from concurrent research
that evaluated different intervention strategies and sampled
embryos at different stages of development. In general wehave observed that approximately 50% of failed eggs
receiving some form of intervention (i.e., reinsemination
or activation, preceded in some cases by in vitromaturation)
undergo cleavage by day 2, with 5–10% of cleaved embryos
reaching the blastocyst stage by days 5–6 (data not shown).
This is comparable to results reportedly previously by others
following reinsemination or activation (Zhang et al., 1999).
Clinically failed eggs have been ruled out for cloning by
somatic cell nuclear transfer by others owing to their lack of
viability, although their utility for this purpose may be
intervention dependent (Lavoir et al., 2005; McElroy et al.,
2008). Our results suggest that the yield of stem cell lines
from clinically failed eggs is likely to be poorer than for other
forms of eggs and embryos reported to date. However, we
believe the quantity of this tissue that is available in a
clinical IVF facility coupled with the fact that it is not
normally considered for the treatment of infertility warrants
renewed consideration of how to optimize its use. Our
successful derivation of a comparably normal hESC line
justifies such an effort.
Our study compared the gene expression profile of
undifferentiated RCM1 hESCs with two lines previously
isolated by our group from surplus to fertility requirements
and genetically related embryos. All three lines were isolates
from whole blastocysts outgrown on feeders with two (RCM1
and RH1) in HDF conditioned Dulbecco's minimal essential
medium (DMEM)) and one (RH3) in a chemically defined
medium, X-Vivo 10 (see Fletcher et al., 2006). This analysis
revealed that RCM1 and RH1 were more closely matched in
their expression of undifferentiated markers, suggesting that
the methods of hESC line isolation and culture conditions
may have a proportionately greater effect on gene expres-
sion than genetic identity. This question has yet to be
systematically addressed by any study published to date and
would likely require a multicenter coordinated action to
achieve a powered analysis such as past and current efforts
by the International Stem Cell Initiative. RCM1 differed from
RH1 and RH3 in expressing significant levels of Xist,
suggesting that a higher proportion of RCM1 cells had
undergone X-chromosome inactivation. However, stable
differences in Xist expression have previously been reported
between other XX hESC lines, namely H7 and 9, with no
apparent consequence to the expression of undifferentiated
markers or differentiation potential (Hoffman et al., 2005).
Accordingly, evaluation of RCM1 pluripotency in vivo and in
vitro conformed to that previously reported for other cell
lines.
Comparative genome hybridization (CGH) analysis did not
reveal any genetic anomaly in RCM1 (i.e., abnormal
structure or copy number). Assessment of G-band chromo-
somes also did not reveal any consistent or reproducible
karyotypic anomalies. Other than trisomy 20 observed on a
single occasion in 1 of 20 spreads, none of the aneuploidies
reported in hESC lines by others were observed, namely,
trisomy 12; gains of chromosomes 12, 14, 17, and X and
chromosome regions 12p, 17q, Xq, and 17q; or alterations of
small regions of 1, 8, 18, or 20 (reviewed by Hanson and
Caisander, 2005). The anomalies that were observed
included losses of chromosomes 1, 4, 8, 9, 12, 24, 17, 20,
and 21 and structural anomalies of chromosomes 5, 6, 13, 16,
and 20. While the former may have been an artifact of
metaphase spread preparation, the latter could have
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detect these reproducibly in independent samples suggests
that they did not have a growth advantage in culture.
In summary our findings support the contention that
clinically failed eggs can and should be considered as a
source of embryos for hESC research. This source of tissue
has less potential to conflict directly with donor reproductive
interests, which ultimately can help promote public accep-
tance of embryo stem cell research, especially in countries
that have more restrictive policies on embryo donation for
nonreproductive purposes.Materials and Methods
This study was approved by participating institutional ethics
advisory boards and conducted under a license from the UK
Human Fertilisation and Embryology Authority (R0136). All
procedures involving animals were conducted in accordance
with the Guidance on the Operations of the Animals
(Scientific Procedures) Act, 1986.
Egg parthenogenetic activation and reinsemination
Failed-to-fertilize eggs were chemically activated by expo-
sure to 5 μM ionomycin (Sigma, Dorset, UK) in G1 medium
(Vitrolife, Göteborg, Sweden) for 5 min at 37 °C. Eggs were
then incubated in 1 mM 6-DMAP (Sigma) and 5 μg/ml
cycloheximide (Sigma) in G1 medium for 3–6 h, under
standard culture conditions (37 °C, 5% CO2). After incuba-
tion, the eggs were placed singly in 50 μl of G1 medium under
oil (Ovoil; Vitrolife). Alternatively, failed-to-fertilize eggs
were microinjected with a single sperm from a donor of
proven fertility (ICSI) before transfer to culture medium as
for activated eggs (G1; Vitrolife). Eggs were checked for the
presence of two pronuclei and the extrusion of the second
polar body 3 and 6 h after activation or 16 to 20 h after
injection. Zygotes were transferred to fresh G1 medium and
cultured in 50-μl drops until day 3, when the embryos were
transferred to G2 medium (Vitrolife). Embryos were graded
every 24 h for up to 7 days.
HESC derivation
At the assisted conception unit embryos were cultivated in
GIII sequential medium (Vitrolife). At 6 days postinsemina-
tion, surplus to infertility treatment blastocyst-stage
embryos were transported in G2 culture medium (Vitrolife)
at 37 °C to Roslin Cells. On receipt, zona pellucida-enclosed
whole embryos were transferred singly into derivation
conditions. If after 2 days in culture the embryos had not
hatched from their zona pellucida (ZP) covering and
attached to the substrates provided, the embryos were
hatched mechanically with the aid of a pipette with or
without Acid Tyrodes (Medicult) to assist with ZP dissolution.
Derivation conditions consisted of 500 μl of medium in four-
well plates (1.9 cm2/well) coated with human laminin
(Sigma) at 2 μg/cm2 seeded with mitotically inactivated
neonatal HDF feeders at 2×104 cells/cm2. Derivation
medium conditions were as described for hESC culture with
HDF conditioned medium (HDF-CM; see below). For alltreatments, media were exchanged 6 days a week. Cells
were passaged by manual dissection of morphologically
undifferentiated colonies until cell cultures had been
expanded to a six-well plate format (9.6 cm2/well) by
approximately passage 8–9 (circa 2 months after embryo
receipt). Sublines of cells were also transitioned to various
feeder-free conditions and passaged with collagenase
(Invitrogen, Paisley, UK) or TrypLE select (Invitrogen).
HESC culture
The principle culture environment supporting RCM1 expan-
sion was HDF-CM on HDF feeders or under feeder-free
conditions described by Xu et al. (2001) except that medium
was preconditioned by HDFs. HDFs were sourced from
neonatal foreskin (Cascade Biologics, Nottinghamshire, UK)
and were cultured according to the manufacturer's protocols
in medium 106 supplemented with Low Serum Growth
Supplement providing 2% (v/v) fetal bovine serum, 1 μg/ml
hydrocortisone, 10 ng/ml epidermal growth factor, 3 ng/ml
basic fibroblast growth factor (bFGF), and 10 μg/ml heparin.
Preparation of HDF-CM involved mitotic inactivation of HDFs
with 5000 rads of γ-irradiation followed by exposure to and
conditioning of fully supplemented KO DMEM/SR medium
(80% Knockout-DMEM, 20% Knockout serum replacement
(Knockout SR), 1 mM glutamine, 0.1 mM β-mercaptoethanol,
1% nonessential amino acids, and 4 ng/ml human bFGF (all
Invitrogen) over 24-h intervals over 7 days. At the time of
usage, HDF-CM that had been harvested and frozen was
thawed, 0.2-μm-filtered for sterility, and supplemented with
an additional 24 ng/ml human bFGF. For feeder-free culture,
RCM1 were grown in HDF-CM on a substrate of either 1:30
diluted growth factor reduced Matrigel (Becton-Dickinson,
Cowley, Oxford, UK) or a mixture of four extracellular matrix
proteins as described by Ludwig et al. (2006), namely laminin
(5 μg/cm2; Sigma), fibronectin (5 μg/cm2; Becton-Dickin-
son), vitronectin (0.2 μg/cm2; Becton-Dickinson), and
collagen IV (10 μg/cm2; Sigma). RCM-1 was also cultured in
StemPro medium (Invitrogen) supplemented with 8 ng/ml
bFGF according to the manufacturer's instructions on HDF
feeders on laminin or on CELLstart (Invitrogen).
Immunocytochemistry
Cells were plated on either four-well glass chambers or
microscope slides precoated with supportive growth sub-
strates and cultured to desired confluence or differentiated.
Cells were washed with PBS before fixation in 4% parafor-
maldehyde in PBS for 20 min at room temperature. Removal
of fix was followed by 2×5-min washes with PBS, and cells
were immunostained immediately or after storage in PBS for
up to 2 weeks. Cells were permeabilized with 100% ethanol
for 2 min at room temperature (OCT4, α-fetoprotein (AFP),
β-tubulin, muscle-specific actin), with 0.3% Triton X-100 for
20 min at room temperature (TH, GFAP, MAP-2), or with 0.1%
saponin for 15 min at room temperature (Nestin) before
immunostaining, followed by two washes with PBS + 0.01%
Tween 20. Before treatment with antibody probes cells were
blocked with PBS containing 10% normal goat serum (NGS)
and 0.01% Tween 20 for 1 h at room temperature. Primary
and secondary antibodies at optimized dilutions were
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tween 20. These were used at room temperature for 1–2 h or
overnight at 4 °C, with unbound antibody removed by 3×5- to
10-min washes in PBS at room temperature. Slides were
mounted in Vectashield containing DAPI (Vector Laboratories,
Peterborough, UK) and stored at 4 °C in the dark prior to being
viewed on a Zeiss S100 Axiovert fluorescence microscope or
Nikon eC1 confocal microscope. Antibody probes consisted of
those specific for AFP (1:500 mouse monoclonal IgG2a;
Sigma), β-tubulin III (1:1000 mouse monoclonal IgG2b;
Sigma), muscle-specific actin (1:50 mouse monoclonal
IgG1κ; DAKO, Glostrup, Denmark), Oct-4 (1:200 mouse
monoclonal IgG2b; Santa Cruz, CA, USA), Nanog (1:20 goat
polyclonal; R&D Systems), Nestin (1:20 mouse monoclonal
IgG1; R&D Systems), TH (1:100 mouse monoclonal IgG1;
Sigma), GFAP (1:600 mouse monoclonal IgG1; Santa Cruz),
MAP-2 (1:100 mouse monoclonal IgG1; Sigma), anti-mouse IgG
(1:200 goat polyclonal IgG-FITC; Sigma), and anti-goat IgG
(1:200 rabbit AlexaFluor-488; Invitrogen). Alkaline phospha-
tase staining was as per the manufacturer's recommended
protocol (Vector Laboratories).
Flow cytometry
Single-cell suspensions of cultured cells were prepared by
treatment with 1 ml of TrypLE select (Gibco Invitrogen) for
5–10 min at 37 °C followed by resuspension in KO DMEM and
aliquotting at 2.5×105 cells per ml for each probe to be
evaluated. Cells were centrifuged at 300 g for 5 min and
resuspended in 50 μl of blocking buffer consisting of 40%
heat-inactivated NGS (Sigma) in flow cytometry (FC) staining
buffer (eBioscience, San Diego, USA). Cells were blocked for
15–30 min at room temperature, followed by addition of
primary antibody probes in FC staining buffer and incubation
on ice for 30 min. Unbound antibody was washed from the
sample by resuspending in FC staining buffer and decanting
following centrifugation at 300 g for 5 min. Treatment with
fluorescent probe-conjugated secondary antibody was in
100 μl of FC staining buffer on ice for 30 min in the dark.
Unbound antibody was removed by addition of PBS, decanted
following centrifugation at 300 g for 5 min. For immediate
assessment on a Becton-Dickinson FACSCAN, cells were
resuspended in 300 μl of PBS. Primary antibody probes
consisted of those specific for SSEA-1 (1:5 mouse monoclonal
IgM; Invitrogen), SSEA-3 (rat monoclonal IgM; Invitrogen),
SSEA-4 (15:50 mouse monoclonal IgG3; Invitrogen), Tra-1-60
(mouse monoclonal IgM; Chemicon, Temecula, CA, USA), Tra-
1-81 (1:29 mouse monoclonal IgM; Chemicon), and CD-9-PE
(mouse monoclonal IgG1κ; BD Pharmingen, San Diego, CA,
USA). Secondary antibody probes consisted of goat anti-
mouse IgG3-FITC (1:100; Southern Biotechnologies, Birming-
ham, AL, USA), goat anti-mouse IgM-PE (1:100; Southern
Biotechnologies), and mouse IgG1-PE (1:100; BD Pharmin-
gen). Isotype controls were mouse monoclonal IgG3 (Sigma),
mouse monoclonal IgM (Sigma), and rat IgM (Southern
Biotechnologies).
Analysis of gene expression
For each hESC line (RCM1, RH1, RH3) RNA was prepared from
three independent biological replicates (±2 weeks, ±4passages) contemporaneously by the same operator. RNA
was isolated using Trizol (Gibco BRL, Paisley, UK) and reverse
transcribed using the Superscript III cDNA synthesis kit
(Invitrogen) according to the manufacturer's instructions
and hybridized to Affymetrix U133plus2 gene chips. Data
were normalized using the RMA algorithm and assessed for
consistency using principal components analysis. Batch
effects attributable to the preparation of samples on
different days were removed to produce a dataset of nine
samples representing three hESC lines that could be analyzed
concurrently. This initial analysis confirmed that biological
replicates behaved consistently within a cell line, and the
only significant cause of variation was the cell line of origin
of a particular set of data. Data were then antilogged (base
2) to obtain a reading for each probe corresponding to the
signal observed on the chip. Probes whose signal was b50
(very low) for all nine samples were filtered out, and the
remaining dataset (∼27,000 probes, or about half the chip)
was used for analysis. After annotation with gene informa-
tion, chromosomal location, and Entrez database reference,
two-way cluster analysis for a set of 40 stem cell markers as
defined by the International Stem Cell Initiative study (ISCI,
2007), together with other lineage markers, was carried out
(see Fig. 2). ANOVA was used to identify differentially
expressed genes between the three hES cell lines.
In vivo differentiation
The developmental potential of RCM1 to form teratomas
consisting of tissues representative of all three germ layers
was evaluated following transplantation in adult SCID mice
using two separate procedures in independent laboratories,
both of which yielded the same result. The first method, the
outcome for which is described in Fig. 1, involved suspension
of approximately 1×106 hESCs in PBS mixed 1:1 with Matrigel
followed by injection beneath the capsule of the testis. After
12 weeks the mice were sacrificed, and tissues were
removed, fixed in Bouins, embedded in paraffin wax, and
sectioned according to standard procedures. Tissue sections
were examined using bright-field light microscopy and digital
images recorded as appropriate. In method 2 (Supplemental
Fig. 3), approximately 2×106 hESCs suspended in PBS alone
were aspirated into PE50 tubing (BD Bioscience) and
transplanted under the kidney capsules of SCID mice. After
8 weeks, the animals were sacrificed and the kidneys
removed and assessed for teratoma formation. Teratoma
was excised from the kidney and the surrounding cyst, fixed
in 4% paraformaldehyde, and embedded in paraffin wax and
serial sections of 7 μm thickness were cut according to
standard procedures. For histological assessment, the tissue
sections were dewaxed, rehydrated, and stained with
Harris's hematoxylin and counterstained with eosin. Sections
were then dehydrated and mounted in DePex mounting
medium. To confirm further that the teratoma contained
tissues derived from the three germ layers, dewaxed and
hydrated serial sections were stained with Safranin O and the
background was stained with 0.02% aqueous Fast Green FCF.
Serial sections were also subjected to antigen retrieval in
citrate buffer, pH 6.0, and stained for antibodies against α-
smooth muscle actin (R&D Laboratories) and neurofilament
(BioMol International, UK) and mounted in Vectashield
mounting medium with DAPI (Vector Laboratories). Tissue
196 P.A. De Sousa et al.sections were analyzed using bright-field and fluorescence
microscopy as appropriate and digital images were recorded.
In vitro differentiation
Embryoid body-mediated differentiation of hESCs involved
dissociation into small clumps by treatment for 10 min in 200
units of collagenase IV in KO DMEM (Invitrogen) at 37 °C
followed by culture for 7 days in suspension on low cluster
plates (Costar, Bethesda, MD, USA) in embryoid body
differentiation medium consisting of 80% KO DMEM (Invitro-
gen), 20% FBS (PAA Laboratories, Pasching, Austria), 1 mM L-
glutamine, 0.1 mM β-mercaptoethanol, 1% nonessential
amino acids (all Invitrogen). The resulting embryoid bodies
were transferred onto glass slide tissue culture chambers
(Nunc, Rochester, NY, USA) coated with 0.5% gelatin at
0.1 ml/cm2 and cultured for an additional 14 days, being fed
every second day, before being fixed and stained. The
neurosphere-mediated differentiation protocol was as per
Ying et al. (2003). Briefly, cells were disaggregated using
collagenase (200 U in KO DMEM for 10 min at 37 °C) and
transferred to low cluster plates containing neuronal
medium—50% DMEM/F12, 50% Neurobasal medium, 1% N2
supplement, 2% B27 supplement, and 1 mM L-glutamine (all
Invitrogen). The cell aggregates were grown for 28 days, with
the medium being exchanged every other day, and then
dissociated using trypsin–EDTA (Invitrogen). The cells were
then transferred to poly-L-lysine/laminin-coated slides (0.1%
poly-L-lysine for 1 h at room temperature followed by 20 μg/
ml laminin overnight at 4 °C) and grown for 5 days in
neuronal medium before being fixed and stained.
DNA and chromosome typing
DNA microsatellite genotyping was carried out by ARK
Genomics (Roslin Biocentre, UK). Genomic DNAwas prepared
using a DNAeasy kit (Qiagen, Hilden, Germany). It was
quantified using an Applied Biosystems Quantifiler Y Male
DNA quantitation kit (Warrington, UK) run on an ABI7599
real-time PCR instrument. Genotyping was performed on
1 ng of genomic DNA using an AmpFLSTR Identifier PCR
amplification kit (Applied Biosystems) as per the manufac-
turer's protocol, run on an ABI Prism 3100 genetic analyzer.
Data were analyzed using GeneMapper 3.1 ID software. Blood
group and HLA genotyping were performed as per SNBTS
Clinical Diagnostic Service protocols according to the method
of Bunce et al. (1995). Cell karyotype was assessed by TDL
Pathology (London, UK). Analysis was periodically performed
approximately every 10 passages, by evaluating 20 meta-
phase spreads of Giemsa-stained chromosomes.
Comparative genome hybridization using
BlueGnome arrayCGH chip
CGH was carried out in collaboration with ARK Genomics
(Roslin Biocentre), using BlueGnome CytoChip arrayCGH
version 2. All procedures were carried out according to the
manufacturer's instructions. RCM1 grown under feeder-free
conditions was harvested using TrypLE Select (Invitrogen)
and pelleted by centrifugation at 300 g for 5 min. DNA was
isolated from RCM1 cell pellets by being resuspended inDNAzol followed by isopropanol, centrifuged at 10,000 g for
10 min, washed with 70% ethanol, air dried, and resuspended
in TE buffer containing 1.1 mM NaOH. The DNA preparation
was quantified, aliquotted at 100 ng/μl, and labeled with
Cy3–dCTP or Cy5–dCTP overnight at 37 °C (BlueGnome
labeling kit). The CytoChip was blocked at 37 °C for 2 h using
blocking solution (15 μg/μl herring sperm DNA in 50%
formamide/10% dextran sulfate) and then hybridized using
the prepared fluorescent dye-labeled DNA preparations
prehybridized in hybridization buffer (2.5 μg/μl human
COT-1 DNA, 15 μg/μl herring sperm DNA in 50% formamide/
10% dextran sulfate) at 37 °C for 24 h. The CytoChips were
washed and scanned using a Molecular Devices Axon 4200AL.
The data were subsequently analyzed using BlueFuse for
Microarray version 3.5 software.
Genome-wide single-nucleotide polymorphism
analysis
Genomic DNA was harvested from RCM1 grown under feeder-
free conditions as described for CGH above. Heterozygosity
frequency and distribution were assessed according to the
method of Kim et al. (2007a,b). Genotypes resulting from
hybridization of RCM1 genomic DNA with GeneChip Human
Mapping 250K Sty I and 250 K Nsp arrays (Affymetrix) were
determined using the BRLMM algorithm implementation in
Genotyping Console version 2.1 (Affymetrix, Santa Clara, CA,
USA) and these were combined into a single 500K analysis file
(CHP file). The resulting CHP files were imported into Partek
Genomics Suite version 6.4 (Partek, St. Louis, MO, USA) and
an unpaired LOH analysis was performed using default
parameters. Comparison of LOH regions between samples
was facilitated by display of LOH regions in genome-wide,
chromosome-specific, or region-specific views within Partek.
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